Editas Medicine is a biotechnology company that operates in the field of gene editing, specifically using a technology known as CRISPR. CRISPR, which stands for "Clustered, Regularly Interspaced, Short Palindromic Repeats," is a technique that allows scientists to precisely edit the DNA in cells, potentially allowing them to correct genetic defects that cause diseases. Editas Medicine is leveraging this technology to develop a pipeline of potential treatments for a variety of serious diseases.

The company's business model revolves around the discovery, development, manufacturing, and commercialization of these genomic medicines. They aim to create transformative and durable treatments that can significantly improve the lives of patients around the world. Their pipeline includes a broad range of experimental medicines, and they regularly present their clinical data at industry events and in company-sponsored webinars.

Editas Medicine's primary clients are patients living with serious diseases that could potentially be treated through gene editing. By developing and commercializing new treatments, the company generates revenue. They also potentially earn income from partnerships with other companies or institutions that are interested in their technology.

In summary, Editas Medicine is a pioneering company in the field of gene editing, using the power of CRISPR technology to develop potential treatments for serious diseases. Their business model is focused on the full cycle of drug development, from discovery to commercialization, and they serve patients around the world who are living with these serious conditions.

Keywords: Editas Medicine, gene editing, CRISPR, biotechnology, genomic medicines, drug development, commercialization, serious diseases, transformative treatments, global patient base.